Chordate Medical Holding AB (OSTO:CMH) ROCE % : -112.69% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Chordate Medical Holding AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -112.69%.

Chordate Medical Holding AB ROCE % Historical Data

The historical data trend for Chordate Medical Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB ROCE % Chart

Chordate Medical Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-206.73

-106.07

-67.32

-112.04

-223.10

Chordate Medical Holding AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-118.51	-88.06	-74.47	-192.23	-112.69

Chordate Medical Holding AB ROCE % Calculation

Chordate Medical Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-29.18	/	( ( (18.641 - 7.568)	+	(21.955 - 6.869) )	/ 2 )
	=	-29.18	/	( (11.073	+	15.086)	/ 2 )
	=	-29.18	/	13.0795
	=	-223.10 %

Chordate Medical Holding AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-24.132	/	( ( (21.955 - 6.869)	+	(34.481 - 6.738) )	/ 2 )
	=	-24.132	/	( ( 15.086	+	27.743 )	/ 2 )
	=	-24.132	/	21.4145
	=	-112.69 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Chordate Medical Holding AB (OSTO:CMH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Chordate Medical Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordate Medical Holding AB (OSTO:CMH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

K1Z:Germany

Address

c/o Regus, Kistagangen 20B, Kista, SWE, 164 40

Website

https://www.chordate.com

Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines